Alpha Cognition Q2 Earnings Call Highlights

Key Points

• ZUNVEYL demand accelerated: Second-quarter product revenue rose 71% sequentially to approximately $6 million, supported by a 37% increase in bottles sold, broader prescriber adoption and a 20% rise in nursing-home facilities ordering the drug.
• Payer access remains the main growth constraint: The company’s contracted open-book coverage stayed at 16%, limiting broader expansion into retail and neurology channels, although repeat orders and underlying demand remained strong.
• Evidence programs and finances progressed: Alpha Cognition reported positive top-line BEACON findings, advanced CONVERGE and RESOLVE, held $41.4 million in cash, and lowered 2026 operating-expense guidance to $50 million-$54 million while maintaining a 2027 operating-profitability target.

Alpha Cognition NASDAQ: ACOG reported second-quarter 2026 net product revenue of approximately $6 million from its Alzheimer’s treatment ZUNVEYL, up about 71% sequentially from $3.5 million in the first quarter, as the company cited growing prescriber adoption and deeper use in long-term care facilities.

Total revenue was $6.1 million, compared with $1.7 million in the prior-year period. GAAP gross product margin was approximately 94%, with cost of product sales totaling roughly $0.4 million. The company recorded a net loss of $8.8 million, or $0.40 per share, improving from a loss of $13.2 million, or $0.82 per share, a year earlier.

“It was a strong quarter of execution with clear sequential growth in ZUNVEYL demand, expansion in prescriber adoption, increased nursing home penetration, and continued progress with evidence generation,” Chief Executive Officer Michael McFadden said on the company’s Aug. 13 earnings call.

Prescription Growth and Facility Adoption

Chief Operating Officer Lauren D’Angelo said second-quarter demand included approximately 8,294 bottles of ZUNVEYL, a 37% increase from the prior quarter. The company reached 8,194 total customers and called on 3,905 prescribers through its approximately 60-person field organization.

Healthcare provider writers—prescribers issuing at least one ZUNVEYL prescription—increased 27% from the first quarter to 1,347. Cumulative life-to-date writers reached 1,908, nearing the company’s approximately 2,000-writer goal for 2026.

Among 1,024 second-quarter writers, approximately 76% placed repeat prescriptions, while prescriptions per writer rose to about six, according to D’Angelo. Nursing homes with ZUNVEYL prescriptions increased 20% sequentially to 1,095, including 346 facilities added during the quarter. About 81% of facilities that ordered the drug placed repeat orders.

D’Angelo said demand increased each month during the quarter, with June representing the strongest month to date. She added that momentum continued into the third quarter, though the company does not provide revenue guidance.

Management said growth was not driven by material inventory stocking at wholesalers or pharmacies. “What you see this quarter is pure demand growth,” D’Angelo said, adding that pharmacies and wholesalers are now generally buying on demand.

Payer Access Remains a Constraint

While ZUNVEYL demand grew, the company said broad formulary activation among downstream payer clients did not materialize at the pace management previously expected. D’Angelo described payer access as the company’s most significant near-term opportunity and friction point.

Alpha Cognition said its contracted open book of business remained at 16%, unchanged from the prior quarter. D’Angelo said the lack of formulary expansion did not appear to constrain underlying demand, given the rise in bottle sales and high facility repeat-order rate.

The company expects payer coverage to be an important factor in any eventual expansion beyond long-term care into retail and neurology settings. D’Angelo said the company is focused on maximizing the long-term care opportunity until it reaches operating profitability, which management continues to target for 2027.

Management also cited the impact of the Inflation Reduction Act on Medicare Part D plans and said this has contributed to the current payer-access environment. The company said it remains hopeful for coverage progress in the second half of 2026 but did not provide a specific timing forecast.

Clinical Evidence Programs Advance

Alpha Cognition reported positive top-line findings from its BEACON study during the quarter. McFadden said providers observed improvements in cognition, neuropsychiatric symptoms and activities of daily living after ZUNVEYL initiation, along with reductions in polypharmacy. The company has submitted the data for presentation at medical meetings and expects publications from the study to be presented this fall.

The company also initiated CONVERGE, a retrospective long-term-care data review, and began patient enrollment in RESOLVE. CONVERGE top-line data are expected during the third quarter of 2026, according to McFadden. He said the study is expected to provide quantitative information on persistence, adherence, polypharmacy, activities of daily living, tolerability and patient profiles across Alzheimer’s treatments.

RESOLVE is recruiting in line with expectations and is expected to complete in the second quarter of 2027, with data anticipated during the summer or fall of that year, McFadden said.

Alpha Cognition is also conducting a comparative pharmacokinetic study for a sublingual formulation during the current quarter. McFadden said results are expected in the third quarter and will determine the timing of the formulation’s clinical program. The company estimates that 10% to 20% of Alzheimer’s patients have swallowing difficulties that could make a sublingual treatment relevant.

Lower Expense Outlook and Balance Sheet

Second-quarter operating expenses totaled $13.5 million, including $11.5 million in selling, general and administrative expenses and $2 million in research and development. The company said spending reflected investments in commercial infrastructure, payer engagement, marketing and evidence-generation programs.

As of June 30, Alpha Cognition had $41.4 million in cash and cash equivalents, $57.9 million in total current assets and $6.4 million in current liabilities, resulting in working capital of approximately $51.5 million.

During the quarter, the company completed an early settlement of Organtus’ former royalty obligation. Chief Financial Officer Henry Du said the transaction eliminates future royalty burdens and is intended to improve the franchise’s future cash flows and economics as ZUNVEYL sales grow.

Alpha Cognition lowered its full-year 2026 operating expense guidance to a range of $50 million to $54 million, from a prior range of $54 million to $58 million. Du said the revision reflects opportunities to operate more efficiently while continuing to support ZUNVEYL’s commercial growth and evidence-generation initiatives.

About Alpha Cognition (NASDAQ:ACOG)

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source